VivoSeq
Other

Recurrent or Metastatic NPC

0

Pipeline Programs↗

5

Active Trials↗

1

Companies Involved↗

Recurrent or Metastatic NPC is an early-stage landscape with 0 programs across 1 company. The most active players are Shanghai Henlius Biotech.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Shanghai Henlius Biotech logo

Shanghai Henlius Biotech

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Recruiting3 · 50%
Not yet recruiting1 · 17%
Active, not recruiting1 · 17%
Unknown status1 · 17%

Clinical Trials

Trial Activity

6 trials

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Recruiting·SSun Yat-sen University·Phase 2·NCT06657690·56 enrolled
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
Recruiting·SSun Yat-sen University·Phase 2·NCT07101744·41 enrolled
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
Recruiting·—·Phase 2·NCT06472713·32 enrolled
Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC
Active, not recruiting·Shanghai Henlius Biotech logoShanghai Henlius Biotech·Phase 2·NCT05513573·75 enrolled
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
Not yet recruiting·SSun Yat-sen University·Phase 3·NCT05780294·132 enrolled
EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC
Unknown status·FFujian Cancer Hospital·Phase 2·NCT03648697·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)